Sonoma Pharmaceuticals (NASDAQ:SNOA) Announces Earnings Results

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its quarterly earnings data on Tuesday. The company reported ($0.48) earnings per share for the quarter, FiscalAI reports. The company had revenue of $4.35 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 20.57% and a negative return on equity of 45.46%.

Sonoma Pharmaceuticals Trading Down 3.4%

Shares of Sonoma Pharmaceuticals stock opened at $2.81 on Wednesday. The company’s fifty day simple moving average is $3.45 and its two-hundred day simple moving average is $3.77. The company has a market cap of $4.78 million, a P/E ratio of -1.28 and a beta of 1.65. Sonoma Pharmaceuticals has a 12-month low of $1.75 and a 12-month high of $6.92.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sonoma Pharmaceuticals presently has an average rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.